Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

RPRX Relative to the S&P 500

RPRX Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Royalty Pharma Plc (NASD:RPRX) seasonal charts above shows that a Buy Date of December 3 and a Sell Date of February 21 has resulted in a geometric average return of 1.47% above the benchmark rate of the S&P 500 Total Return Index over the past 4 years. This seasonal timeframe has shown positive results compared to the benchmark in 3 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 4 years by an average of 25.32% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 4 years of data is available for shares of RPRX, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J s Imbruvica, Astellas and Pfizer s Xtandi, Biogen s Tysabri, Gilead s HIV franchise, Merck s Januvia, Novartis Promacta, Vertex s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

To download RPRX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: RPRX